Fig. 6.

circPTPRA suppresses EMT in NSCLC cell lines via regulating the miR-96-5p/RASSF8/E-cadherin axis.

(a) circPTPRA and miR-96-5p levels correlate inversely (R = −0.8241, R² = 0.6792 [Spearman correlation]) in patient-derived NSCLC tumors (n = 80). (b) Typical IHC images of RASSF8 and E-cadherin protein levels in patient-derived NSCLC tumors stratified by circPTPRA expression; scale bar = 50 μm. (c and d) circPTPRA positively correlate with (c) RASSF8 transcript levels and (d) E-cadherin transcript levels in patient-derived NSCLC tumors (n = 80). (e and f) Kaplan-Meier univariate analysis of (e) overall survival and (f) disease-free survival (DFS) in NSCLC patients with high (above median) versus low (below median) miR-96-5p tumor levels (n = 40 in each group). *p < .05, **p < .01 [log rank test]. (g) miR-96-5p levels in NSCLC lymph node metastasis (n = 32) and non-metastatic NSCLC tumors (n = 48); *p < .05, **p < .01 [unpaired Student's t-test].

Data presented as means with error bars representing standard errors of the mean (SEMs). Abbreviations: DFS = disease-free survival, EMT = epithelial-mesenchymal transition, RASSF8 = Ras association domain-containing protein 8.